Lv1
20 积分 2023-10-08 加入
FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors
3天前
求助中
Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer
3天前
求助中
Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
10天前
已完结
CSF Biopsy in Glioma: A Brief Review
10天前
已完结
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
22天前
已关闭
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
22天前
已关闭
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
22天前
已关闭
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
23天前
已完结
Adénocarcinome œsogastrique – nouvelles cibles thérapeutiques
1个月前
已完结
FGFR Inhibitor Stymies Gastric Cancer
1个月前
已完结
皖公网安备34019202002308
